Comparative utility of interferon-γ release assay, QuantiFERON® TB-GIT and T-SPOT®.TB in rheumatoid arthritis

被引:5
作者
Matsumura, R. [1 ]
Igari, H. [2 ,3 ]
Nakazawa, T. [1 ]
Ishikawa, S. [2 ]
Tsuyuzaki, M. [4 ]
Suzuki, K. [4 ]
Yamagishi, F. [2 ]
机构
[1] Natl Hosp Org Chiba East Hosp, Ctr Rheumatol Allergy & Clin Immunol, Chiba, Japan
[2] Natl Hosp Org Chiba East Hosp, Dept Resp Med, Chiba, Japan
[3] Chiba Univ Hosp, Div Infect Control, Chiba, Japan
[4] Chiba Fdn Hlth Promot & Dis Prevent, Chiba, Japan
关键词
rheumatoid arthritis; IGRA; latent tuberculous infection; immunosuppressive condition; TNF-alpha blocker; LATENT TUBERCULOSIS INFECTION; NECROSIS-FACTOR ANTAGONISTS; IMMUNOSUPPRESSIVE THERAPY; AUTOIMMUNE-DISEASES; SKIN-TEST; PERFORMANCE; DIAGNOSIS; RISK; GOLD; METAANALYSIS;
D O I
10.5588/ijtld.16.0038
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SETTING: National hospital for tuberculosis (TB) and rheumatoid arthritis (RA) in Japan. OBJECTIVE: To compare two interferon-gamma release assays (IGRAs), QuantiFERON(R)-TB Gold In-Tube (QFT) and T-SPOT(R).TB (T-SPOT), in RA patients for detecting latent tuberculous infection (LTBI). DESIGN: QFT and T-SPOT were conducted concurrently in 230 prospectively enrolled RA patients. RESULTS: There were no active TB patients. The percentage of QFT- and T-SPOT-positive patients was respectively 8.3% and 5.7%. In patients aged >= 60 years, these proportions were respectively 12.3% and 7.2%. The percentage of QFT positivity and T-SPOT positivity at age <60 years was respectively 2.2% and 3.3%. After multivariate logistic analysis for QFT positivity, age >= 60 years and TB suspected based on chest X-ray were selected as independent factors, with adjusted odds ratios of respectively 4.73 and 3.25. No factors were selected for T-SPOT positivity. CONCLUSION: QFT had a higher positivity rate. In the light of the previous estimated rate of LTBI in Japan, both IGRAs underestimate LTBI, and neither IGRA has enough capability to detect LTBI.
引用
收藏
页码:1546 / 1553
页数:8
相关论文
共 44 条
  • [41] Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
    Hsia, Elizabeth C.
    Schluger, Neil
    Cush, John J.
    Chaisson, Richard E.
    Matteson, Eric L.
    Xu, Stephen
    Beutler, Anna
    Doyle, Mittie K.
    Hsu, Benjamin
    Rahman, Mahboob U.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (07): : 2068 - 2077
  • [42] Evaluation of risk factors for false-negative results with an antigen-specific peripheral blood-based quantitative T cell assay (T-SPOT®.TB) in the diagnosis of active tuberculosis: A large-scale retrospective study in China
    Yang, Chi
    Zhang, Shaojun
    Yao, Lan
    Fan, Lin
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (05) : 1815 - 1825
  • [43] Application of Interferon-γ Release Assay in the Assessment of T-Cell Immunity to SARS-CoV-2 Antigens in the Cohort of Pediatric Patients with Juvenile Idiopathic Arthritis
    Kapten, Katarzyna
    Orczyk, Krzysztof
    Smolewska, Elzbieta
    CHILDREN-BASEL, 2024, 11 (06):
  • [44] Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production
    Alessio, Grazia
    Imeneo, Alessandra
    Di Lorenzo, Andrea
    Rossi, Benedetta
    Sorace, Chiara
    Compagno, Mirko
    Coppola, Luigi
    Campogiani, Laura
    Crea, Angela Maria Antonia
    Malagnino, Vincenzo
    Buccisano, Francesco
    Andreoni, Massimo
    Sarmati, Loredana
    Iannetta, Marco
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):